

# Market Announcement

14 March 2024

---

## PYC Therapeutics Limited (ASX: PYC) – Trading Halt

### Description

The securities of PYC Therapeutics Limited ('PYC') will be placed in trading halt at the request of PYC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 18 March 2024 or when the announcement is released to the market.

### Issued by

ASX Compliance



## REQUEST FOR TRADING HALT

ASX Limited  
Central Park  
152-158 St Georges Terrace  
PERTH WA 6000

By Email: [tradinghaltsperth@asx.com.au](mailto:tradinghaltsperth@asx.com.au)

### **PYC Therapeutics Limited ('PYC') – Request for Trading Halt**

In accordance with Listing Rule 17.1, PYC requests that an immediate trading halt be placed on its securities pending an announcement to the market regarding a proposed capital raising.

The Company anticipates that the trading halt will be lifted on or before market open on Monday 18 March 2024 by provision of an announcement to ASX regarding the proposed capital raising.

PYC is not aware of any reason why the trading halt should not be granted, nor of any other information relevant to this request.

Yours sincerely

Andrew Taylor  
Company Secretary

### **About PYC Therapeutics**

PYC Therapeutics (ASX: PYC) is a biotechnology company creating a new generation of RNA therapies by combining its drug design capabilities with a proprietary drug delivery platform.

The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and pre-clinical discovery programs focused on neurodevelopmental and kidney diseases. PYC's discovery, pre-clinical and laboratory operations are in Australia and its translational, clinical, and

regulatory operations are in the United States. For more information, visit [pyctx.com](https://pyctx.com), or follow us on [LinkedIn](#) and [Twitter](#).

*This ASX announcement was approved and authorized for release by the Board of PYC Therapeutics Limited*

**CONTACT:**

info@pyctx.com